Online Media Kit
FEATURED STORY
March 16, 2022 | Times LIVE (South Africa)
The South African Health Products Regulatory Authority (SAHPRA) okayed the use of the monthly dapivirine vaginal ring by adult women.
FEATURED STORY
February 26, 2022 | The East African (Kenya)
Given a choice between two HIV prevention products, most adolescent girls and young women who had used both products while participating in the REACH study chose the monthly dapivirine ring.
FEATURED STORY
January 26, 2021 | World Health Organization
WHO recommended that the dapivirine vaginal ring, a female-initiated option to reduce the risk of HIV infection, may be offered as an additional prevention choice for women at substantial HIV risk as...
Media Highlights
March 04, 2022 | POZ
Previous research has shown low rates of use of HIV prevention products, but the tide could be turning.
March 03, 2022 | The Independent (Uganda)
The REACH study has found that when young women have access to and experience with two biomedical prevention options, the dapivirine vaginal ring and oral PrEP, almost all of them choose to continue...
February 26, 2022 | The East African (Kenya)
Given a choice between two HIV prevention products, most adolescent girls and young women who had used both products while participating in the REACH study chose the monthly dapivirine ring.
February 17, 2022 | MedPage Today
In the REACH trial, 67% of adolescent girls and young women preferred to use the dapivirine vaginal ring, 31% were happy with oral PrEP, and just 2% weren't interested in either method.
February 16, 2022 | Times LIVE (South Africa)
New results from the REACH study show that the majority, or 67% of young women in Africa, chose the vaginal ring over daily HIV pre-exposure prophylaxis pills.